Schedule Update - effective 1 September 2008 (text extract)

This is the text extract for Schedule Update - effective 1 September 2008, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 September 2008 Section H cumulative for August and September 2008

Contents

Summary of PHARMAC decisions effective 1 September 2008 ...................... 3 Extension of the $3 Prescription Co-payment................................................ 5 New General Rules ........................................................................................ 6 Concerta – newly listed product for ADHD .................................................... 7 Topiramate – Now Subsidised for Prophylaxis of Migraines ........................... 7 Risperidone – widened access ....................................................................... 8 New Treatment for Basal Cell Carcinoma and Genital Warts ......................... 8 Erythropoietin alpha and beta – Special Authority now interchangeable ...... 8 Habitrol Lozenges ......................................................................................... 9 Acarbose ....................................................................................................... 9 New Brand of Clopidogrel ............................................................................. 9 Insulin Glargine (Lantus SoloStar) – new delivery device ............................... 9 Poloxamer ..................................................................................................... 9 Name change for atenolol ........................................................................... 10 Tender News ................................................................................................ 10 Looking Forward ......................................................................................... 11 Sole Subsidised Supply products cumulative to September 2008................ 13 New Listings ................................................................................................ 19 Changes to Restrictions ............................................................................... 21 Changes to Subsidy and Manufacturer’s Price............................................. 25 Changes to Brand Name ............................................................................. 26 Changes to General Rules............................................................................ 27 Changes to Sole Subsidised Supply ............................................................. 27 Delisted Items ............................................................................................. 28 Items to be Delisted .................................................................................... 29 Section H changes to Part II ........................................................................ 31 Section H changes to Part IV ....................................................................... 34 Index ........................................................................................................... 35

Summary of PharmaC decisions

effeCtive 1 SePtemBer 2008 New listings (pages 19 to 20) • Insulin glargine (Lantus SoloStar) inj 100 iu per ml, 3 ml disposable pen, Special Authority – Retail pharmacy • Erythropoietin alpha (Eprex) inj human recombinant 5,000 iu pre-filled syringe and 6,000 iu pre-filled syringe – Special Authority – Hospital pharmacy [HP3] • Clopidogrel (Apo-Clopidogrel) tab 75 mg – Special Authority – Retail pharmacy • Losartan (Cozaar) tab 25 mg 30 tablet pack – Special Authority Retail pharmacy • Atenolol (Pacific Atenolol) tab 50 mg and 100 mg • Nicotine (Habitrol) lozenge 1 mg and 2 mg – Only on a Quitcard • Imiquimod (Aldara) cream 5% sachets – Special Authority – Retail Pharmacy • Amitriptyline (Amirol) tab 10 mg • Methylphenidate hydrochloride extended-release (Concerta) tab extendedrelease 18 mg, 27 mg, 36 mg and 54 mg – Special Authority – Retail pharmacy Changes to restriction (pages 21 to 24) • Acarbose – amended Special Authority criteria • Erythropoietin alpha – amended Special Authority criteria • Growth hormone biosynthetic human – addition of stat • Recombinant human growth hormone – addition of stat • Topiramate – removal of Special Authority criteria • Risperidone tabs and oral liq – removal of Retail pharmacy – Specialist • Risperidone microspheres for injection – amended Special Authority criteria • Risperidone orally-disintegrating tablets – amended Special Authority criteria • Methylphenidate hydrochloride – amended presentation description Decreased subsidy (pages 25 to 26) • Calcium carbonate (Calci-Tab Effervescent) tab dispersible 2.5 g • Iron polymaltose (Ferrosig) inj 50 mg per ml, 2 ml • Erythropoietin alpha (Eprex) inj human recombinant 1,000 iu pre-filled syringe, 2,000 iu pre-filled syringe, 3,000 iu pre-filled syringe, 4,000 iu pre-filled syringe, 10,000 iu pre-filled syringe • Paracetamol oral liq 120 mg per 5 ml (Junior Parapaed) and oral liq 250 mg per 5 ml (Six Plus Parapaed) • Topiramate (Topamax) tab 25 mg, 50 mg, 100 mg, and 200 mg, sprinkle cap 15 mg and 25 mg • Risperidone (Risperdal) tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg

Summary of PharmaC decisions – effective 1 September 2008 (continued) • Calcium folinate (Baxter) inj 1 mg for ECP • Fludarabine phosphate (Fludara) inj 50 mg • Methotrexate (Methotrexate Ebewe) inj 100 mg per ml, 10 ml and 50 ml • Polyvinyl alcohol eye drops 1.4% (Vistil) and eye drops 3% (Vistil Forte) increased subsidy (pages 25 to 26) • Nitrofurantoin (Nifuran) tab 50 mg and 100 mg • Lithium carbonate (Priadel) tab long-acting 400 mg • Fludarabine phosphate (Fludara) tab 10 mg

Pharmaceutical Schedule - Update News

Extension of the $3 Prescription Co-payment

In 2008, the Minister announced as part of the Budget that the Government was going to extend access to $3 co-payments on prescriptions.

As of 1 September 2008, the Government will continue the implementation of the Primary Health Care Strategy by introducing this policy extension to reduce prescription co-payments. Under this policy extension a person who is eligible for publicly funded health services in New Zealand under the Eligibility Direction (refer to www.moh.govt.nz/ eligibility) is eligible for a $3 co-payment on prescriptions for fully subsidised medicines if the prescription is issued by: 1. A Practitioner employed by a District Health Board (e.g. hospital or District Health Board community-based services); 2. A provider/Practitioner with an access or service agreement with the Ministry of Health or a District Health Board (DHB) or a Primary Health Organisation (PHO); 3. An After Hours provider with an access or service agreement with a PHO or a DHB; 4. A provider providing a fully publicly funded service under a Section 88 alone. The policy extension is intended to apply to all registered health practitioners who have prescribing rights under the Health Practitioners Competence Assurance Act 2003 including, but not limited to, medical practitioners, midwives, nurses and dentists. Exclusions to the policy extension are:

1. Providers providing privately funded services; 2. Providers providing services that are not fully publicly funded under a Section 88 notice alone (for example, general practitioners who are not part of a PHO and private specialists). There is a new category of ‘eligible person and eligible provider/prescriber’. The ‘eligible person and eligible provider/prescriber’ category will be coded Y4, J4 or A4 depending on the age group of the patient. The usual rules and provisions associated with the High Use Health Card (HUHC), Community Services Card (CSC) and Pharmaceutical Subsidy Card (PSC) will continue to apply for persons who are not included in other categories of eligibility. Prescriptions should be correctly coded by the prescriber. Pharmacists are not required to identify or validate whether a particular prescription is correctly coded under this category. However, all prescriptions from public hospitals will be eligible for the $3 (or $0 for children under the age of 6 years) and pharmacists may override any public hospital prescriptions that are coded incorrectly.

6 Pharmaceutical Schedule - Update News

New General Rules

The General Rules of the Pharmaceutical Schedule have been amended from 1 September 2008. The new rules will mean that pharmacists will not need prescribers to initial the prescription when they (the pharmacist) has substituted and dispensed a fully funded brand when the prescription was initially written for a non-subsidised brand – as long as they have a valid authority to substitute from the prescriber. The authority must be either a general written authority or written or verbal authority for a specific prescription. Where a prescriber has included on the bottom of a prescription “Generic Substitution Allowed” or similar, this is seen as an indication of an Authority to Substitute and is applicable to all items on the form. Where a prescriber has issued an Authority to Substitute but wants a specific brand to be dispensed for a specific product or patient the prescriber may indicate on the prescription that no substitution is allowed. The prescriber should make it clear which particular items on the prescription this applies to. A updated Authority to Substitute letter template was faxed to pharmacies with the Dispatch on 18th September 2008. It will be published in the December 2008 Pharmaceutical Schedule and is available now on the PHARMAC website www.pharmac. govt.nz. The other change to the General Rules is in relation to cases where the presentation of a pharmaceutical is amended. This is a formalisation of the Pharmacy Procedures Manual rule 4.11 regarding changing the presentation of pharmaceutical dispensed. If there is an amendment to the prescription which means a higher cost to the DHB then the prescriber must sign the alteration. However, if due to an out of stock or short supply situation, PHARMAC notifies pharmacists that a certain presentation may be claimed in place of a short supply product, then there is no requirement for the prescriber to sign the change. For example if a 400 mg tablet is out of stock, 2 x 200 mg tablets may be dispensed. See page 27 of this Update for details. We appreciate the feedback we received and acknowledge the time people took to respond. Following consultation, the dafting of the proposal rule change was amended to reflect some of the feedback we received. • Many consultation responses raised the issue of the need to get the prescribers authority to substitute one brand for another and suggested that this be removed altogether. This is a legal requirement under the section 42(4) of the Medicines Regulations 1984. Changing the Medicines Regulations was beyond the scope of this proposal. • Some consultation responses suggested that the wording of the proposed rule be changed to include provision for where a prescriber has given authority (verbal or written) in relation to a particular prescription.

Pharmaceutical Schedule - Update News

The wording of the rule has been amended from that which was consulted on to cover such situations. • Some consultation responses suggested that the wording of the Authority to Substitute letter be amended to cover situations where only one brand of a pharmaceutical is listed and is not covered by a sole supply arrangement. The wording of the Authority to Substitute letter has been amended accordingly. • Some consultation responses suggested that the wording of the proposed “Alteration to Quantity Dispensed” rule might incorrectly be interpreted as meaning that pharmacists may alter the total period of supply of a

prescription. The wording of this rule has been amended to “Alteration to Presentation Dispensed” to avoid this confusion. • Some consultation responses pointed out that there may be times when changing the frequency of dosing may be necessary. For example if a sustained release product is out of stock, a twice daily dosing of a lower strength may be an appropriate alternative. The wording of this rule has been amended accordingly. • Some consultation responses requested that we widened pharmacists ability to make endorsements to prescriptions. Changing endorsement criteria was beyond the scope of this proposal.

Concerta – newly listed product for ADHD

A once-a-day treatment for people with ADHD (Attention Deficit Hyperactivity Disorder) is being funded from 1 September 2008. Concerta, extended-release methylphenidate, will be the third form of methylphenidate funded for people with ADHD. The currently funded preparations (immediate-release and sustained-release) are effective treatments for ADHD; however, some patients need to take several doses a day and problems with compliance can lead to reduced efficacy. Concerta will be fully subsidised for people who have not responded well to the two other funded methylphenidate preparations because of compliance difficulties, and for people in whom there is a risk of diversion of the immediate-release preparation. See page 20 of this update for full details.

Topiramate – Now Subsidised for Prophylaxis of Migraines

People having trouble controlling persistent migraines will have a new treatment option from 1 September 2008. PHARMAC is removing the Special Authority criteria for topiramate (Topamax), an existing funded treatment for epilepsy, so that it can also be used to prevent migraines. This is the second new treatment option for migraine sufferers that PHARMAC has provided this year. The widening of access to topiramate means it will also now be funded as a first-line treatment for epilepsy. With the relatively large number of treatments available for people with migraines, and the drug’s side-effects, topiramate is likely to be used as “last resort” for people with migraines.

8 Pharmaceutical Schedule - Update News

Risperidone – widened access

Risperidone tablets and oral liquid will no longer be subject to a “Retail pharmacy – Specialist’ restriction from 1 September 2008. They will be subsidised when prescribed by any relevant practitioner. Additionally, the Special Authority criteria for risperidone orally-disintegrating tablets (Risperdal Quicklets) will be amended to remove the requirement for a psychiatrist to submit Special Authority applications and to write the first prescription. The Special Authority restriction applying to risperidone microspheres for injection (Risperdal Consta) will be amended to remove the requirement for a psychiatrist to make the application.

New Treatment for Basal Cell Carcinoma and Genital Warts

A new treatment is being funded for people with a generally non-malignant form of skin cancer. Imiquimod (Aldara) is a cream that people can apply themselves to treat basal-cell carcinoma. While surgery remains the most effective treatment for skin cancers, imiquimod is useful in treating people for whom surgery might be inappropriate. Imiquimod has also been funded for the treatment of genital warts. Imiquimod (Aldara) will be fully subsidised by Special Authority, from 1 September 2008, for patients who: • have confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or • have external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated) or where podophyllotoxin is unable to be applied accurately to the site. Imiquimod will be listed in the newly named Wart Preparations section of the Dermatologicals therapeutic group in Section B of the Pharmaceutical Schedule. See page 19 of this Update for full details.

Erythropoietin alpha and beta – Special Authority now interchangeable

The Special Authority criteria that currently apply to erythropoietin beta will also apply erythropoietin alpha from 1 September 2008. Erythropoietin alpha and erythropoietin beta will be interchangeable under this Special Authority from 1 September 2008. The price and subsidy for all strengths of Eprex (erythropoietin alpha) will be reduced from 1 September 2008 and two new strengths will be listed. All will be fully subsisided.

Pharmaceutical Schedule - Update News

Habitrol Lozenges

A new presentation of Habitrol will be subsidised from 1 September 2008. Habitrol lozenges, a nicotine replacement therapy, will be subsidised when ordered on a QuitCard.

Acarbose

The Special Authority criteria applying to acarbose has been changed with effect from 1 September 2008. The applicant type has been amended from relevant specialist only, to any relevant practitioner. In addition the need for renewal of the Special Authority has been removed. See page 21 of this Update for full details.

New Brand of Clopidogrel

A new brand of the antiplatelet agent clopidogrel will be listed in the Pharmaceutical Schedule from 1 September 2008. Apo-Clopidogrel will be fully subsidised for patients meeting the existing Special Authority criteria for clopidogrel. The Plavix brand of clopidogrel will continue to be listed. The subsidy for Plavix will be reduced from 1 October 2008 to the same level as that of Apo-Clopidogrel.

Insulin Glargine (Lantus SoloStar) - new delivery device

Lantus SoloStar – a pre-filled cartridge for the administration of insulin glargine will be listed on the Pharmaceutical Schedule under the existing Special Authority from 1 September 2008. Lantus SoloStar will be supplied as an alternative device to the freely supplied Owen Munford pen that will also continue to be available. The new delivery device incorporates a number of new and improved features compared with existing insulin pen devices.

Poloxamer

Poloxamer 10% oral drops (Coloxyl) is currently listed in the Pharmaceutical Schedule. There have been manufacturing delays and Coloxyl is not currently available in the market. The sole supply status date for Coloxyl will be delayed until the product is available.

Name change for atenolol

Pacific Pharmaceuticals is changing the name of its atenolol product, Loten, to Pacific Atenolol. Both Loten and Pacific Atenolol will be listed and fully subsidised until March 2009 when the Loten brand will be delisted.

tender News

Sole Subsidised Supply changes – effective 1 October 2008

Chemical Name Brimonidine tartrate Calcium folinate Clotrimazole Desmopressin Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Emulsifying ointment Flucanozole Flucanozole Flucanozole Gliclazide Glipizide Hydrocortisone Hydrocortisone with wool fat and mineral oil Methylprednisolone acetate Methylprednisolone acetate with lignocaine Metoclopramide hydrochloride Miconazole nitrate Norethisterone Presentation; Pack size Eye drops 0.2%; 5 ml OP Inj 50 mg; 5 inj Crm 1%; 20 g OP Nasal spray 10 mcg per dose; 6 ml OP Eye drops 1 mg per ml; 5 ml OP Suppos 12.5 mg; 10 suppos Suppos 25 mg; 10 suppos Suppos 50 mg; 10 suppos Suppos 100 mg; 10 suppos Inj 25 mg per ml, 3 ml; 5 inj Oint BP; 500 g Cap 50 mg; 28 cap Cap 150 mg; 1 cap Cap 200 mg; 28 cap Tab 80 mg; 500 tab Tab 5 mg; 100 tab Crm 1%; 500 g Lotn 1% with wool fat hydrous 3% and mineral oil; 250 ml Inj 40 mg per ml, 1 ml; 1 inj Inj 40 mg per ml with lignocaine 1 ml; 1 inj Inj 5 mg per ml, 2 ml; 10 inj Crm 2%; 15 g OP Tab 5 mg; 100 tab Sole Subsidised Supply brand (and supplier) AFT (AFT) Calcium Folinate Ebewe (InterPharma) Clomazol (Multichem) Desmopressin-PH&T (AFT) Voltaren Ophtha (Novartis) Voltaren (Novartis) Voltaren (Novartis) Voltaren (Novartis) Voltaren (Novartis) Voltaren (Novartis) AFT (AFT) Pacific (Pacific) Pacific (Pacific) Pacific (Pacific) Apo-Gliclazide (Apotex) Minidiab (Pfizer) PSM (API) DP Lotn HC (Douglas) Depo-Medrol (Pfizer) Depo-Medrol with Lidocaine (Pfizer) Pfizer (Pfizer) Multichem (Multichem) Primolut N (Bayer)

Sole Subsidised Supply changes – effective 1 October 2008 (continued)

Chemical Name Pamidronate disodium Pamidronate disodium Pamidronate disodium Pergolide Pergolide Terbinafine Testosterone cypionate Tetracosactrin Tetracosactrin Triamcinolone acetonide Ursodeoxycholic acid Presentation; Pack size Inj 3 mg per ml, 5 ml; 1 inj Inj 6 mg per ml, 10 ml; 1 inj Inj 9 mg per ml, 10 ml; 1 inj Tab 0.25 mg; 100 tab Tab 1 mg; 100 tab Tab 250 mg; 100 tab Inj long-acting 100 mg per ml, 10 ml; 1 inj Inj 250 mcg; 10 inj Inj 1 mg per ml, 1 ml; 1 inj 0.1% in Dental Paste USP; 5 g OP Cap 300 mg; 100 cap Sole Subsidised Supply brand (and supplier) Pamisol (Mayne) Pamisol (Mayne) Pamisol (Mayne) Permax (Anspec) Permax (Anspec) Apo-Terbinafine (Apotex) Depo-Testosterone (Pfizer) Synacthen (Novartis) Synacthen Depot (Novartis) Oracort (AFT) Actigall (Novartis)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 October 2008 • Acipimox (Olbetam) cap 250 mg – removal of ‘Retail pharmacy – specialist’ • Amiloride (Biomed) oral liq 1 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist.’ • Aminoacid formula without phenylalanine (Lophlex LQ) – with Special Authority Criteria • Calcium polystyrene sulphonate powder (Calcium Resonium) – removal of ‘Retail pharmacy – specialist’ • Candesartan (Atacand) – amended Special Authority criteria • Chlorothiazide (Biomed) oral liq 50 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist’ • Clozapine (Clopine) 25 mg, 50 mg, 100 mg and 200 mg – new listing of 100 tablet bottle pack • Dipyridamole tab 25 mg (Persantin) and tab long-acting 150 mg (Pytazen SR) – amended Special Authority criteria • Folic acid oral liq 50 µg per ml (Biomed) – removal of ‘Retail pharmacy – specialist. Specialist must be a paedatrician or paediatric cardiologist’

Possible decisions for implementation 1 October 2008 (continued) • Frusemide (Lasix) infusion 10 mg per ml, 25 ml – removal of ‘Retail pharmacy – specialist’ • Heparin sodium inj 25,000 iu per ml, 0.2 ml (Mayne) – removal of ‘Hospital pharmacy [HP3] – specialist’ and increased subsidy • Heparin sodium injection 5,000 iu per 5 ml (Multiparin) – increased subsidy • Midodrine (Gutron) – amended Special Authority criteria • Peak flow meter (Breath-Alert), low range and normal range – decreased subsidy • Plavix (clopidogrel) tab 75 mg – subsidy decrease • Potassium bicarbonate (Phosphate-Sandoz) tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg – removal of ‘Retail pharmacy – specialist’ • Pravastatin (Pravachol)– amended Special Authority criteria • Risperidone (Ridal) Tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg – new listing of 60 tablet bottle pack • Simvastatin (SimvaRex) tab 80 mg – new listing • Sodium polystyrene powder (Resonium-A) – removal of ‘Retail pharmacy – specialist’ • Spacer device (Space Chamber) 230 ml (autoclavable) – decreased subsidy and addition of endorsement criteria • Spacer device (Space Chamber) 230 ml (single patient) – new listing – only on a WSO • Spironolactone (Biomed) oral liq 5 mg per ml – removal of ‘Retail pharmacy – specialist. Specialist must be a paediatrician or paediatric cardiologist.’

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Aciclovir Alprazolam

Presentation

Tab dispersible 200 mg Tab dispersible 400 mg Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 100 mg Tab dispersible 300 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Scalp app 0.1% Tab 5 mg Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Cap 0.25 µg & 0.5 µg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg

Brand Name Expiry Date*

Lovir Lovir Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Apo-Ascorbic Acid Ethics Aspirin Ethics Aspirin EC Loten AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Beta Scalp Lax-Tab Marcain Isobaric Marcain Heavy ABM ABM Calcitriol-AFT Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor PSM Chlorsig Chlorsig Orion Orion Hygroton Klamycin Klacid Dermol Clomazol PSM Colgout 2009 2010

Apomorphine hydrochloride Amoxycillin

2009 2010 2009 2009 2010 2009 2009 2009 2009 2009 2010 2010 2009 2009 2010 2010 2010 2009 2009 2009 2010 2009 2010 2010 2010

Ascorbic acid Aspirin Atenolol Atropine sulphate Azithromycin Beclomethasone dipropionate Betamethasone valerate Bisacodyl Bupivicaine hydrochloride Calamine Calcitriol Captopril Cefaclor monohydrate Cetomacrogol Chloramphenicol Chlorhexidine gluconate Chlorthalidone Clarithromycin Clobetasol propionate Clotrimazole Codeine phosphate Colchicine

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose Dextrose with electrolytes

Presentation

Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Mayne PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Apo-Diclo Apo-Diclo SR Videx EC Apo-Doxazosin m-Enalapril Mayne Cafergot New Zealand Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Staphlex AFT AFT 2009 2010 2009 2010 2010 2010 2009 2010 2009 2009 2010 2009 2010 2011 2010

Dicloflenac sodium Didanosine (DDI) Doxazosin mesylate Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Ethinyloestradiol Ethinyloestradiol with norethisterone

Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab 2 mg & 4 mg Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Tab 10 µg Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml

2009 2009 2010 2009 2009 2009 2009 2010

Etoposide Ferrous sulphate Flucloxacillin sodium

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 14

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Presentation

Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml TDDS 5 mg TDDS 10 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Oral liq 100 mg per 5 ml, 200 ml Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg

Brand Name Expiry Date*

Ultraproct Ultraproct 2010

Fluorometholone Fluoxetine hydrochloride Folic Acid Fusidic acid Gentamicin sulphate Glyceryl trinitrate Haloperidol

Flucon Fluox Fluox Apo-Folic Acid Foban Pfizer Nitroderm TTS 5 Nitroderm TTS 10 Serenace Serenace Serenace AstraZeneca Douglas Colifoam Locoid Fenpaed Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Duride Isotane 10 Isotane 20 Sporanox Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250

2009 2010 2009 2010 2009 2011 2010 2009 2009 2009 2009 2010 2010 2009 2009 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Ibuprofen Imipramine hydrochloride Indapamide Ipratropium bromide

Isosorbide mononitrate Isotretinoin Itraconazole Lactulose Levobunolol Levodopa with benserazide

2009 2009 2010 2010 2010 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 15

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Lignocaine hydrochloride

Presentation

Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M A-Lices Ludiomil Provera Pentasa Arrow-Metformin Methatabs AFT Methoblastin Rubifen SR Rubifen Rubifen Medrol Advantan Solu-Medrol Solu-Medrol Solu-Medrol Slow-Lopresor Metopirone Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph 2009 2010 2010 2010

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate Methylphenidate hydrochloride

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Tab 2.5 mg & 10 mg Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Tab long-acting 200 mg Cap 250 mg Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml

2009 2009 2010 2010 2009 2010 2009 2009 2010 2009 2009 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone sodium succinate Metoprolol tartrate Metyrapone Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2009

2009 2009 2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 16

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Morphine sulphate

Presentation

Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg Tab 350 µg Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Mayne Mayne Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard Noriday 28 Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Lacri-Lube Loxamine Pexsig 2009 2010 2010 2009 2010 2010 2009 2009 2009 2009 2010 2009 2010 2010 2010 2009 2011 2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine Norethisterone Nystatin

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pantoprazole

2010

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Perhexiline maleate

Eye oint with soft white paraffin Tab 20 mg Tab 100 mg

2010 2010 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 17

Sole Subsidised Supply Products – cumulative to September 2008

Generic Name

Phenoxymethylpenicillin (Penicillin V)

Presentation

Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Tab long-acting 600 mg Tab 1 mg, 2 mg & 5 mg Cassette Tab 50 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 150 mg & 300 mg Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Eye drops 0.25% Eye drops 0.5% Tab 10 mg Tab 50 mg Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml

Brand Name Expiry Date*

AFT AFT Cilicaine VK Cilicaine VK Prefrin Span-K Apo-Prazo MDS Quick Card Apo-Pyridoxine Q 200 Q 300 Peptisoothe Mycobutin Arrow-Roxithromycin Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Apo-Timop Apo-Timop Apo-Timol Apo-Thiamine Kenacomb 2010

Phenylephrine hydrochloride Potassium chloride Prazosin hydrochloride Pregnancy tests - HCG urine Pyridoxine hydrochloride Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin Salbutamol

2010 2009 2010 2009 2009 2009 2010 2010 2009 2009 2010 2009 2009 2009 2010 2009 2009 2010 2011 2009 2009 2009

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Timolol maleate

Thiamine hydrochloride Triamcinolone acetonide with gramicidin, neomycin and nystatin Vincristine sulphate Vitamins Vitamin B complex Water September changes in bold type.

Mayne Mayne Healtheries Apo-B-Complex Multichem

2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 18

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 August 2008

75 MEDROXYPROGESTERONE ACETATE ❋ Inj 150 mg per ml, 1ml – Up to 5 inj available on a PSO ............. 8.05 1 ✔ Depo-Provera

Effective 1 September 2008

29 43 INSULIN GLARGINE – Special Authority see SA0834 – Retail pharmacy ▲ Inj 100 iu per ml, 3 ml disposable pen ..................................... 94.50 5 ✔ Lantus SoloStar

ERYTHROPOIETIN ALPHA – Special Authority SA0922 – Hospital pharmacy [HP3] Inj human recombinant 5,000 iu, pre-filled syringe ................. 243.26 6 Inj human recombinant 6,000 iu, pre-filled syringe ................. 291.92 6 CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy Tab 75 mg .............................................................................. 35.00 LOSARTAN – Special Authority see SA0911 – Retail pharmacy ❋ Tab 25 mg .............................................................................. 21.76 ATENOLOL ❋ Tab 50 mg ................................................................................ 6.50 ❋ Tab 100 mg ............................................................................ 11.30 NICOTINE – Only on a Quitcard Lozenge 1 mg ......................................................................... 11.08 Lozenge 2 mg ......................................................................... 11.08 28 30 500 500 36 36

✔ Eprex ✔ Eprex

45 55 56

✔ Apo-Clopidogrel

✔ Cozaar ✔ Pacific Atenolol ✔ Pacific Atenolol ✔ Habitrol ✔ Habitrol

IMIQUIMOD – Special Authority see SA0923 – Retail pharmacy Crm 5 % ................................................................................ 110.40 12 sachets ✔ Aldara ➽ SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 4 months for Applications meeting the following criteria: Either: 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate. Note Superficial basal cell carcinoma Surgical excision remains remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance. Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears. Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma. External anogenital warts Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata). Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2008 (continued)

continued... 1 Inadequate response to initial treatment for anogenital warts; or 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or 3 Inadequate response to initial treatment for superficial basal cell carcinoma. Note Confirmation that the lesion is a superficial basal cell carcinoma should be obtained using a biopsy.

109 128

AMITRIPTYLINE Tab 10 mg ................................................................................ 2.77

✔ Amirol

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority SA0924 – Retail Pharmacy Only on a controlled drug form Tab extended-release 18 mg .................................................... 58.96 30 ✔ Concerta Tab extended-release 27 mg .................................................... 65.44 30 ✔ Concerta Tab extended-release 36 mg .................................................... 71.93 30 ✔ Concerta Tab extended-release 54 mg .................................................... 86.24 30 ✔ Concerta ➽ SA0924 Special Authority for Subsidy Initial application only from a paediatrician, psychiatrist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder); and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist; and 4 Either: 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediaterelease or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride. Renewal only from a paediatrician, psychiatrist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 September 2008

29 ACARBOSE - Special Authority see SA04900925 – Retail pharmacy ❋ Tab 50 mg .............................................................................. 22.00 90 ✔ Glucobay ❋ Tab 100 mg ............................................................................ 31.00 90 ✔ Glucobay ➽ SA08740925 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years without renewal for applications meeting the following criteria: 1 The patient has type 2 diabetes; and 2 Either: 2.1 Metformin is not tolerated, or is contraindicated; or 2.2 The patient has not responded to the maximum appropriate dose of metformin. Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. ERYTHROPOIETIN ALPHA – Special Authority see SA09220626 – Hospital pharmacy [HP3] ➽ SA0626 Special Authority for Subsidy Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under under evaluation for, or awaiting, a live donor kidney transplant; and 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low cardiac output, LV ejection fraction <40%); or 4.6.2.2 Persistent angina Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. ➽ SA0922 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin ≤ 100g/L; and 2 Any of the following: 2.1 Both: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

continued... 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate ≤ 30ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate ≤ 45ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over: GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l) GFR (ml/min) (female) = Estimated GFR (male) × 0.85 84 GROWTH HORMONE BIOSYNTHETIC HUMAN – Special Authority see SA0755 (addition of stat dispensing) ❋ Cartridge 16 iu per vial........................................................ 1,600.00 5 ✔ Genotropin ❋ Cartridge 36 iu per vial........................................................ 3,600.00 5 ✔ Genotropin RECOMBINANT HUMAN GROWTH HORMONE – Special Authority see SA0755 (addition of stat dispensing) ❋ Inj 5 mg ................................................................................ 300.00 1 ✔ Norditropin SimpleXx 5mg ❋ Inj 10 mg .............................................................................. 600.00 1 ✔ Norditropin SimpleXx 10mg ❋ Inj 15 mg .............................................................................. 900.00 1 ✔ Norditropin SimpleXx 15mg TOPIRAMATE – Special Authority see SA0874 – Retail pharmacy ➽ SA0874 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatmentwith other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy priorto 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient hasdemonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate,vigabatrin and or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success withanticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrateda significant and sustained improvement in seizure rate or severity and or quality of life. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

114

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

continued... Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success withanticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. RISPERIDONE – Retail Pharmacy – Speciaist Tab 0.5 mg ............................................................................... 5.20 Tab 1 mg ................................................................................ 30.77 Tab 2 mg ............................................................................... 61.53 Tab 3 mg ............................................................................... 92.32 Tab 4 mg ............................................................................. 123.05 Oral liquid 1 mg per ml ............................................................ 45.92 20 60 60 60 60 30 ml OP ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Risperdal

120

121

RISPERIDONE – Special Authority see SA09260792 – Retail pharmacy Subject to budgetary cap. Applications will be considered and approved subject to funding availability. Microspheres for injection 25 mg........................................... 175.00 1 ✔ Risperdal Consta Microspheres for injection 37.5 mg........................................ 230.00 1 ✔ Risperdal Consta Microspheres for injection 50mg............................................ 280.00 1 ✔ Risperdal Consta ➽ SA09260792 Special Authority for Subsidy Initial application only from a psychiatrist from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had less than 12 months treatment with risperidone microspheres; and 1.2 There is no clinical reason to discontinue treatment; or 2 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. Note: Risperidone microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone microspheres.

122

RISPERIDONE – Special Authority see SA09270794 – Retail pharmacy Orally-disintegrating tablets 0.5 mg .......................................... 21.42 Orally-disintegrating tablets 1 mg ............................................. 42.84 Orally-disintegrating tablets 2 mg ............................................. 85.71

28 28 28

✔ Risperdal Quicklet ✔ Risperdal Quicklet ✔ Risperdal Quicklet

➽ SA09270794 Special Authority for Subsidy Initial application - (Acute situations) only from a psychiatrist from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

continued... 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and 2 The patient is under direct supervision for administration of medicine. Initial application - (Chronic situations) only from a psychiatrist from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Renewal only from a psychiatrist from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners. Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary. 127 METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA0908 – Retail Pharmacy Only on a controlled drug form Tab immediate-release 5 mg.................................................... 3.20 30 ✔ Rubifen Tab immediate-release 10 mg.................................................. 4.29 30 ✔ Rubifen Tab immediate-release 20 mg.................................................. 7.85 30 ✔ Rubifen Tab long acting sustained-release 20 mg ............................... 10.95 30 ✔ Rubifen SR

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 September 2008

38 CALCIUM CARBONATE ( subsidy) ❋ Tab dispersible 2.5 g ................................................................. 4.36 (4.98) IRON POLYMALTOSE ( subsidy) Inj 50 mg per ml, 2 ml ............................................................. 20.95 (29.95) 20 OP Calci-Tab Effervescent 5 Ferrosig

ERYTHROPOIETIN ALPHA – Special Authority see SA0922 – Hospital pharmacy [HP3] ( subsidy) Inj human recombinant 1,000 iu, pre-filled syringe ................... 48.68 6 ✔ Eprex Inj human recombinant 2,000 iu, pre-filled syringe ................. 120.18 6 ✔ Eprex Inj human recombinant 3,000 iu, pre-filled syringe ................. 166.87 6 ✔ Eprex Inj human recombinant 4,000 iu, pre-filled syringe ................. 193.13 6 ✔ Eprex Inj human recombinant 10,000 iu, pre-filled syringe ............... 395.18 6 ✔ Eprex POTASSIUM BICARBONATE – Retail pharmacy – Specialist ( price) Tab eff 315 mg with sodium acid phosphate with 1.937 g and sodium bicarbonate 350 mg ................................................ 75.00 (82.50) PHENTOLAMINE MESYLATE ( price) ❋ Inj 10 mg per ml, 1 ml ............................................................. 17.97 (31.65) NITROFURANTOIN ( subsidy) ❋ Tab 50 mg .............................................................................. 17.90 ❋ Tab 100 mg ............................................................................ 30.25 PARACETAMOL ( subsidy) ❋ Oral liq 120 mg per 5ml ............................................................ 6.80 ❋ Oral liq 250 mg per 5 ml ............................................................ 7.00 TOPIRAMATE ( subsidy) ▲ Tab 25 mg .............................................................................. 26.04 ▲ Tab 50 mg .............................................................................. 44.26 ▲ Tab 100 mg ............................................................................ 75.25 ▲ Tab 200 mg .......................................................................... 129.85 ▲ Sprinkle cap 15 mg ................................................................. 20.84 ▲ Sprinkle cap 25 mg ................................................................. 26.04 LITHIUM CARBONATE ( subsidy) Tab long–acting 400 mg .......................................................... 16.05 RISPERIDONE ( subsidy) Tab 0.5 mg ............................................................................... 5.20 Tab 1 mg ................................................................................ 30.77 Tab 2 mg ................................................................................ 61.53 Tab 3 mg ................................................................................ 92.32 Tab 4 mg .............................................................................. 123.05

100 5

Phosphate-Sandoz

Regitine 100 100 1,000 ml 1,000 ml 60 60 60 60 60 60 100 20 60 60 60 60

✔ Nifuran ✔ Nifuran ✔ Junior Parapaed ✔ Six Plus Parapaed

107

114

✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax

119 120

✔ Priadel

✔ Risperdal ✔ Risperdal ✔ Risperdal ✔ Risperdal ✔ Risperdal

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 September 2008 (continued)

131 132 132 133 CALCIUM FOLINATE ( subsidy) Inj 1 mg for ECP – PCT only – Specialist .................................... 0.10 FLUDARABINE PHOSPHATE – PCT only – Specialist ( subsidy) Tab 10 mg ............................................................................ 650.25 FLUDARABINE PHOSPHATE – PCT only – Specialist ( subsidy) Inj 50 mg ............................................................................ 1430.00 METHOTREXATE – PCT – Hospital pharmacy [HP1] – Specialist ( subsidy) Inj 100 mg per ml, 10 ml – PCT Only – Specialist .................... 27.50 Inj 100 mg per ml, 50 ml – PCT Only – Specialist .................. 135.00 POLYVINYL ALCOHOL ( subsidy) ❋ Eye drops 1.4% ........................................................................ 2.68 ❋ Eye drops 3% ........................................................................... 3.75 1 mg 15 5 1 1 ✔ Baxter

✔ Fludara

✔ Fludara ✔ Methotrexate Ebewe ✔ Methotrexate Ebewe ✔ Vistil ✔ Vistil Forte

154

15 ml OP 15 ml OP

Changes to Brand Name

Effective 1 September 2008

43 ERYTHROPOIETIN BETA – Special Authority SA0922 – Hospital pharmacy [HP3) Inj 2,000 iu pre-filled syringe ................................................. 152.04 6 Inj 3,000 iu pre-filled syringe ................................................. 228.06 Inj 4,000 iu pre-filled syringe ................................................. 304.08 Inj 5,000 iu pre-filled syring ................................................... 380.10 Inj 6,000 iu pre-filled syringe ................................................. 456.12 Inj 10,000 iu pre-filled syringe ............................................... 760.20 6 6 6 6 6 ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon

continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 September 2008

12 “Authority to Substitute” means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule. 4.7 Substitution Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer’s Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to: a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or b) the Practitioner having indicated their Authority to Substitute on the prescription; or c) the Practitioner having given their Authority to Substitute in relation to the particular prescription. Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and initial the prescription. 4.8 Alteration to Presentation of Pharmaceutical Dispensed A Contractor, when dispensing a Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed but may not alter the total daily dose. If the change will result in additional cost to the DHBs, then: a) the Practitioner must authorise and initial the alteration; or b) in cases where PHARMAC has approved and notified in writing such a change in dispensing of a named Pharmaceutical due to an out of stock event or short supply, the Contractor must annotate and initial the alteration. 4.9 4.7 Amendment of the Schedule PHARMAC may amend the terms of the Schedule from time to time by notice in writing given in such manner as PHARMAC thinks fit, and in accordance with such protocols as agreed with the Pharmacy Guild of New Zealand (inc) from time to time. 4.10 4.8 Conflict of Provisions If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

Changes to Sole Subsidised Supply

Effective 1 September 2008

For the list of new Sole Subsidised Supply products effective 1 September 2008 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 13-18.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 September 2008

37 ASCORBIC ACID AND SODIUM ASCORBATE a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg ............................................................................. 2.60 PERMETHRIN Lotion 5% .................................................................................. 4.50 (7.00) ECONAZOLE NITRATE Pessaries 150 mg with applicators ........................................... 2.75 (9.71) BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO........... 16.00 160 Note: Bicillin LA continues to be listed fully subsidised ACICLOVIR ❋ Tab 200 mg ............................................................................. 7.92 ❋ Tab 400 mg ........................................................................... 11.86 SAQUINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Cap 200 mg ......................................................................... 271.00

100 50 ml OP

✔ Healtheries Vitamin C

Quellada-P 3 Pevaryl Ovules 1 10 ✔ Bicillin ✔ Bicillin

100 100 180

✔ Apo-Acyclovir ✔ Apo-Acyclovir ✔ Fortovase

99 106

ASPIRIN ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ...... 21.50 (22.50) 1000 Ethics Aspirin ❋ Tab EC 650 mg ........................................................................ 6.88 100 ✔ Ecotrin Note: the 100 tablet pack of Ethics Aspirin, tab dispersible 300 mg will continue to be listed fully subsidised ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hospital pharmacy [HP3] Powder (vanilla) sachet 54 g ..................................................... 6.91 10 OP ✔ Fortisip Powder

170

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2008

38 CALCIUM ❋ Tab eff 1 g................................................................................. 6.54 CALCIUM CARBONATE ❋ Tab dispersible 2.5 g ................................................................. 4.36 (4.98) IRON POLYMALTOSE Inj 50 mg per ml, 2 ml ............................................................. 20.95 (29.95) ZINC AND CASTOR OIL Ointment BP .............................................................................. 5.11 PARACETAMOL ❋‡ Oral liq 120 mg per 5 ml ....................................................... 6.80 a) Up to 200 ml available on a PSO b) Not in combination ❋‡ Oral liq 250 mg per 5 ml ....................................................... 7.00 30 ✔ Calcium-Sandoz 1000

20 OP Calci-Tab Effervescent 5 Ferrosig 500 g 1,000 ml 1,000 ml ✔ Multichem ✔ Junior Parapaed ✔ Six Plus Parapaed

66 107

Effective 1 March 2009

43 47 54 56 ERYTHROPOIETIN BETA – Special Authority see SA0922 – Hospital pharmacy [HP3] Inj 1,000 iu, pre-filled syringe ................................................. 76.02 6 HEPARINISED SALINE ❋ Inj 100 iu per ml, 5 ml .......................................................... 103.76 LOSARTAN ❋ Tab 25 mg .............................................................................. 20.31 ATENOLOL ❋ Tab 50 mg ............................................................................... 6.50 ❋ Tab 100 mg ........................................................................... 11.30 VERAPAMIL HYDROCHLORIDE ❋ Tab 40 mg ................................................................................ 4.75 NICOTINE – Only on a Quitcard Gum 2 mg (Fruit) .................................................................... 23.41 Gum 2 mg (Mint) .................................................................... 23.41 Gum 4 mg (Fruit) ..................................................................... 23.41 Gum 4 mg (Mint)..................................................................... 23.41 ERYTHROMYCIN LACTOBIONATE Inj 300 mg ............................................................................. 70.97 SAQUINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Cap 200 mg .......................................................................... 519.75 Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. 50 28 500 500 100 96 96 96 96 5 270 ✔ Recormon ✔ Mayne ✔ Cozaar ✔ Loten ✔ Loten ✔ Verpamil ✔ Nicotinell ✔ Nicotinell ✔ Nicotinell ✔ Nicotinell ✔ Mayne ✔ Invirase

59 61

90 99

▲

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 March 2009 (continued)

109 125 AMITRIPTYLINE Tab 10 mg ................................................................................ 3.00 NITRAZEPAM – Month Restriction Tab 5 mg .................................................................................. 2.00 (3.90) SALBUTAMOL Tab long-acting 4 mg .............................................................. 11.18 DIBROMOPROPAMIDINE ISETHIONATE ❋ Eye oint 0.15% ......................................................................... 2.97 (7.99) 100 100 Insoma 56 5 g OP Brolene ✔ Volmax ✔ Amitrip

150 154

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 September 2008

AMANTADINE HYDROCHLORIDE Cap 100 mg ...................................Symmetrel AMITRIPTYLINE Tab 10 mg......................................Amirol ATENOLOL Tab 50 mg......................................Pacific Atenolol Tab 50 mg......................................Loten Tab 100 mg ...................................Pacific Atenolol 47.81 2.77 6.50 60 50 500 1% Sept-06 Anselol Apo-Atenolol Golbal Atenolol Anselol Apo-Atenolol Golbal Atenolol 1% Oct-08 (B)

11.30

500

Sept-06

Tab 100 mg....................................Loten Please note that the Loten brand of atenolol tablets 50 mg and 100 mg will be delisted from 1 September 2008. AQUEOUS (new listing) Cream ............................................AFT 1.49 100 g 1% Nov 08 Orion Multichem PSM

Note – Multichem brand of aqueous cream 100 g will be delisted from 1 November 2008 CLOPIDOGREL (new listing) Tab 75 mg......................................Apo-Clopidogrel DIPYRIDAMOLE Tab long-acting 150 mg ......................Pytazen SR EMULSIFYING OINTMENT (new listing) Ointment BP ...................................AFT ERYTHROPOIETIN ALPHA (new listing) Inj human recombinant 1,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 2,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 3,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 4,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 5,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 6,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 10,000 iu, pre-filled syringe ........................Eprex 35.00 11.52 2.50 100 g 28 1% 1% Oct-08 Nov 08 Persantin (B)

48.68 120.18 166.87 193.13 243.26 291.92 395.18

6 6 6 6 6 6 6

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 September 2008 (continued)

ERYTHROPOIETIN BETA (change to brand name) Inj 2,000 iu prefilled syringe ............NeoRecormon Recormon Inj 3,000 iu prefilled syringe ............NeoRecormon Recormon Inj 4,000 iu prefilled syringe ............NeoRecormon Recormon Inj 5,000 iu prefilled syringe ............NeoRecormon Recormon Inj 6,000 iu prefilled syringe ............NeoRecormon Recormon Inj 10,000 iu prefilled syringe ..........NeoRecormon Recormon FLUDARABINE ( price) Tab 10 mg......................................Fludara FLUDARABINE PHOSPHATE ( price) Inj 50 mg........................................Fludara IMIQUIMOD (new listing) Cream 5 %, sachet .........................Aldara 152.04 228.06 304.08 380.10 456.12 760.20 6 6 6 6 6 6 5% 5% 5% 5% 5% 5% Apr-06 Apr-06 Apr-06 Apr-06 Apr-06 Apr-06 (B) (B) (B) (B) (B) (B)

650.25 1430.00 110.40

15 5 12 5 1 1

1% 1%

Nov 08 Nov 08

(B) (B)

INSULIN GLARGINE Inj 100 iu per ml, 3 ml ....................Lantus SoloSTAR 94.50 METHOTREXATE ( price and HSS addition) Inj 100 mg per ml, 10 ml ................Methotrexate Ebewe Inj 100 mg per ml, 50 ml ................Methotrexate Ebewe 27.50 135.00

1% 1%

Nov-08 Nov-08

Hospira Hospira

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE (new listing) Tablet extended-release 18 mg .......Concerta 58.96 30 Tablet extended-release 27 mg .......Concerta 65.44 30 Tablet extended-release 36 mg .......Concerta 71.93 30 Tablet extended-release 54 mg .......Concerta 86.24 30 NICOTINE Lozenge 1 mg ................................Habitrol Lozenge 2 mg ................................Habitrol PRILOCAINE HYDROCHLORIDE Inj 0.5%, 50 ml ...............................Citanest Inj 0.5%, 50 ml ...............................Citanest 11.08 11.08 80.00 160 36 36 5 10

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 September 2008 (continued)

RISPERIDONE ( price) Tab 0.5 mg.....................................Risperdal Tab 1 mg........................................Risperdal Tab 2 mg........................................Risperdal Tab 3 mg........................................Risperdal Tab 4 mg........................................Risperdal SODIUM CHLORIDE (new listing) Soln 0.9% for irrigation ...................Pfizer TOPIRAMATE (new listing) Tab 25 mg......................................Topamax Tab 50 mg......................................Topamax Tab 100mg.....................................Topamax Tab 200mg.....................................Topamax Sprinkle cap 15 mg.........................Topamax Sprinkle cap 25 mg.........................Topamax 5.20 30.77 61.53 92.32 123.05 20.00 26.04 44.26 75.25 129.85 20.84 26.04 20 60 60 60 60 30 ml 60 60 60 60 60 60 1% Nov 08 Orion

Effective 1 August 2008

ADALIMUMAB (new listing) Inj 40 mg per 0.8 ml prefilled pen ...............................HumiraPen

1,799.92

2 Oct-08 Oct-08 Oct-08 AFT AFT AFT

CEFOTAXIME (new listing) Inj 500 mg......................................Cefotaxime Sandoz 1.69 1 1% Inj 1 g.............................................Cefotaxime Sandoz 1.90 1 1% Inj 2 g.............................................Cefotaxime Sandoz 2.60 1 1% Note - AFT brand of cefotaxime inj, 1 g & 2 g will be delisted 1 October 2008. GLYCERYL TRINITRATE Tab 600 µg ....................................Lycinate IVERMECTIN (new listing) Tab 3 mg........................................Stromectol KETOCONAZOLE (new listing) Shampoo 2 % .................................Sebizole METHOTREXATE Inj 100 mg per ml, 5 ml ..................Methotrexate Ebewe METRONIDAZOLE Suppos 1 g.....................................Flagyl 8.00 25.96 3.48 100 4 100 ml 1% 1% 1%

Sept-08 Oct-08 Oct-08

(B) (B) Ketopine Nizoral

18.00

33.31

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 August 2008 (continued)

PACLITAXEL (new listing) Inj 30 mg .......................................Paclitaxel Ebewe 37.95 Inj 100 mg......................................Paclitaxel Ebewe125.35 Inj 600 mg......................................Paclitaxel Ebewe724.50 PACLITAXEL ( price and addition of HSS) Inj 150 mg......................................Paclitaxel Ebewe188.03 Inj 300 mg......................................Paclitaxel Ebewe376.05 1 1 1 1 1 1% 1% 1% 1% 1% Oct-08 Oct-08 Oct-08 Oct-08 Oct-08 Anzatax Taxol Anzatax Taxol (B) Anzatax Taxol Anzatax Taxol

Note - The Taxol brand of paclitaxel inj 150 mg & 300 mg will be delisted from 1 October 2008.

Section H changes to Part IV

Effective 1 September 2008

CEFUROXIME AXETIL Tab 250 mg Oral liq 125 mg per 5 ml Up to 2 weeks supply for any appropriate indication CEFUROXIME SODIUM Tab 250 mg Oral liq 125 mg per 5 ml Up to 2 weeks supply for any appropriate indication Inj 250 mg Inj 750 mg Inj 1.5 g For any indication approved by the hospital service, with review at 6 weeks.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Acarbose ........................................................... 21 Aldara .......................................................... 19, 32 Aciclovir ............................................................ 28 Adalimumab....................................................... 33 Amantadine hydrochloride .................................. 31 Amirol .......................................................... 20, 31 Amitrip ............................................................... 30 Amitriptyline ........................................... 20, 30, 31 Apo-Acyclovir .................................................... 28 Apo-Clopidogrel ........................................... 19, 31 Aqueous ............................................................ 31 Ascorbic acid and sodium ascorbate .................. 28 Aspirin ............................................................... 28 Atenolol ................................................. 19, 29, 31 B Benzathine benzylpenicillin ................................. 28 Bicillin ................................................................ 28 Brolene .............................................................. 30 C Calcium ............................................................. 29 Calci-Tab Effervescent ................................. 25, 29 Calcium-Sandoz 1000 ........................................ 29 Calcium carbonate ....................................... 25, 29 Calcium folinate ................................................. 26 Cefotaxime......................................................... 33 Cefotaxime Sandoz ............................................ 33 Cefuroxime axetil................................................ 34 Cefuroxime sodium ............................................ 34 Citanest ............................................................. 32 Clopidogrel .................................................. 19, 31 Concerta ...................................................... 20, 32 Cozaar ......................................................... 19, 29 D Depo-Provera ..................................................... 19 Dibromopropamidine isethionate ........................ 30 Dipyridamole........................................................ 31 E Ecotrin ............................................................... 28 Emulsifying ointment .......................................... 31 Econazole nitrate ................................................ 28 Eprex ..................................................... 19, 25, 31 Erythromycin lactobionate .................................. 29 Erythropoietin alpha.......................... 19, 21, 25, 31 Erythropoietin beta ................................. 26, 29, 32 Ethics Aspirin ..................................................... 28 F Ferrosig ....................................................... 25, 29 Flagyl ................................................................. 33 Fludara......................................................... 26, 32 Fludarabine ........................................................ 32 Fludarabine phosphate ................................. 26, 32 Fortisip Powder .................................................. 28 Fortovase ........................................................... 28 G Genotropin ......................................................... 22 Glucobay ........................................................... 21 Glyceryl trinitrate ................................................ 33 Growth hormone biosynthetic human ................. 22 H Habitrol ........................................................ 19, 32 Healtheries Vitamin C ......................................... 28 Heparinised saline .............................................. 29 HumiraPen ......................................................... 33 I Imiquimod ................................................... 19, 32 Insoma .............................................................. 30 Insulin glargine ............................................. 19, 32 Invirase .............................................................. 29 Iron polymaltose .......................................... 25, 29 Ivermectin .......................................................... 33 J Junior Parapaed ........................................... 25, 29 K Ketoconazole ..................................................... 33 L Lantus SoloStar ........................................... 19, 32 Lithium carbonate .............................................. 25 Losartan ...................................................... 19, 29 Loten ........................................................... 29, 31 Lycinate ............................................................. 33 M Medroxyprogesterone acetate............................. 19 Methylphenidate hydrochloride extended-release ....................................... 20, 32 Methotrexate .......................................... 26, 32, 33 Methotrexate Ebewe ..................................... 26, 32 Methylphenidate hydrochloride ........................... 24 Metronidazole .................................................... 33 N NeoRecormon .............................................. 26, 32 Nicotine ................................................. 19, 29, 32 Nicotinell ............................................................ 29 Nifuran ............................................................... 25 Nitrazepam......................................................... 30 Nitrofurantoin ..................................................... 25 Norditropin SimpleXx 5mg .................................. 22 Norditropin SimpleXx 10mg ................................ 22 Norditropin SimpleXx 15mg ................................ 22 O Oral supplement 1kcal/ml ................................... 28 P Pacific Atenolol ............................................ 19, 31 Paclitaxel ........................................................... 34

Index

Pharmaceuticals and brands Paclitaxel Ebewe ................................................ 34 Paracetamol................................................. 25, 29 Permethrin ......................................................... 28 Pevaryl Ovules ................................................... 28 Phentolamine mesylate ...................................... 25 Phosphate-Sandoz ............................................. 25 Polyvinyl alcohol ................................................ 26 Potassium bicarbonate ....................................... 25 Priadel ............................................................... 25 Prilocaine hydrochloride ..................................... 32 Pytazen SR ........................................................ 31 Q Quellada-P ......................................................... 28 R Recombinant human growth hormone ................ 22 Recormon .............................................. 26, 29, 32 Regitine ............................................................. 25 Ridal .................................................................. 23 Risperdal ............................................... 23, 25, 33 Risperdal Consta ................................................ 23 Risperdal Quicklet .............................................. 23 Risperidone............................................ 23, 25, 33 Rubifen .............................................................. 24 Rubifen SR ........................................................ 24 S Salbutamol......................................................... 30 Saquinavir .................................................... 28, 29 Sebizole ............................................................. 33 Six Plus Parapaed ........................................ 25, 29 Sodium chloride ................................................. 33 Stromectol ......................................................... 33 Symmetrel ......................................................... 31 T Topamax...................................................... 25, 33 Topiramate............................................. 22, 25, 33 V Verapamil hydrochloride ..................................... 29 Verpamil ............................................................ 29 Vistil .................................................................. 26 Vistil Forte .......................................................... 26 Volmax .............................................................. 30 Z Zinc and castor oil .............................................. 29

Pharmaceutical Management Agency Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 September 2008

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 September 2008 Section H cumulative for August and September 2008 Contents Summary of PHARMAC decisions effective 1 September 2008 …. 3 Extension of the $3 Prescription Co-payment… 5 New General…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.